Wednesday, July 8, 2026

Drug profile · INN

dantrolene sodium

dantrolene sodium (DANTRIUM) is a ryanodine receptor 3 antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 11
Pipeline programs 1
News articles 0
Drug details — dantrolene sodium
US status
approved
Class
Route
INJECTION
Patents
11
Programs
1
Data quality
0.89

Quick answer

dantrolene sodium (DANTRIUM) is a ryanodine receptor 3 antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN dantrolene sodium
Brand DANTRIUM
Mechanism Ryanodine receptor 3 antagonist
Target Ryanodine receptor 1
Route INJECTION
Formulation CAPSULE

Mechanism of action

Ryanodine receptor 3 antagonist

Primary target: Ryanodine receptor 1

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. FTP-CLIN-01 Phase 2 · Anaxis Pharma · glabellar lines.

Related & competitor drugs

  1. dantrolene sodium, hemiheptahydrate Musculo-skeletal system (M03)
  1. US 12364693

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12295394

    Water-soluble additive composition

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11389444

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10213388

    Abuse resistant oral dosage forms

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9125822

    Particle for medical use and process for producing the same

    Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9056054

    Abuse resistant oral dosage forms

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8703186

    Abuse-resistant oral dosage forms and method of use thereof

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8529257

    Aerosolized ceramic porcelains and glaze composition

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8425933

    Abuse-resistant oral dosage forms and method of use thereof

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8182836

    Abuse-resistant oral dosage forms and method of use thereof

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 7018465

    Aerosolized ceramic porcelains and glaze composition

    Expires Mon Mar 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is dantrolene sodium?

dantrolene sodium (DANTRIUM) is a ryanodine receptor 3 antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for dantrolene sodium?

DANTRIUM is a marketed brand name for dantrolene sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dantrolene sodium?

dantrolene sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.